Former President, Innovation & Technology · Revance Therapeutics, Inc. (RVNC)

Aubrey Rankin

FY2021 is the first fiscal year CompBrief holds for Aubrey Rankin as a named executive officer of Revance Therapeutics; the record below is that year, complete. Every figure below is printed as the company filed it and cited to the filing it came from.

Total disclosed compensation, FY2021

$2,983,291

Salary $395,000Stock awards $1,432,424

3rd of 6 named executive officers at Revance Therapeutics by FY2021 total.

6 named officers on file for Revance Therapeutics, FY2021

Aubrey Rankin’s pay file — $29

  • 1 fiscal year of pay, line by line
  • 8 equity grants, each cited to its filing
  • RVNC’s disclosed peer group of 20 companies

A PDF and a CSV sent to your email. Every row is cited to its filing.

One-time report. No refunds.

See an example →

Velarion Intel · free for 3 days · no card

See how Revance Therapeutics’s whole pay program stands against its peers

  • Revance Therapeutics’s company dashboard and its AI-written, board-ready brief, every figure cited to the filing
  • Peer-group intelligence, custom peer reruns and governance screens
  • Every other company we cover, with alerts when they file
Start my free trial on RVNC→

No card. Nothing is charged, and the trial ends on its own.

Compensation figures as of the proxy filed March 24, 2022 (DEF 14A).

Free

Get Aubrey Rankin’s full pay file as a PDF — free

More than this page: up to 10 years of Aubrey’s pay history, a side-by-side peer comparison, and a one-page board summary — the whole file, yours now and by email.

Aubrey Rankin compensation by year

Revance Therapeutics Summary Compensation Table · the one fiscal year held
In US dollars, as Revance Therapeutics reports it. Most recent year shaded. Totals are the company’s disclosed totals.
ComponentFY2021
Salary$395,000
Bonus$0
Stock awards$1,432,424
Option awards$669,632
Non-equity incentive$159,086
Pension and deferred compensation$0
All other$327,149
Total$2,983,291

Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: Revance Therapeutics, Inc. DEF 14A filed March 24, 2022, accession 0001479290-22-000048, and prior-year filings. Open the filing on EDGAR.

How this page was built: the Revance Therapeutics, Inc. filed document, accession 0001479290-22-000048. Every figure is read from that document and cited to the page and table it appears in. Filed March 24, 2022.

Equity holdings

unvested awards at FY2021 year-end
TypeUnvested unitsValue at year-endExercise price
RSU42,938$700,748—
PSU11,905$194,290—
RSU11,905$194,290—
Option17,053—$28.01

Per the Outstanding Equity Awards at Fiscal Year-End table in Revance Therapeutics, Inc.'s FY2021 proxy; value at the fiscal year-end close, as the company printed it.

Revance Therapeutics’s named executive officers, FY2021

as the company reported each
Named executive officerRoleFY2021 total
Mark FoleyChief Executive Officer$7,105,916
Dustin SjutsPresident$3,230,411
Aubrey Rankin · this pageFormer President, Innovation & Technology$2,983,291
Abhay JoshiChief Operating Officer, President of R&D and Product Operations$2,586,759
Tobin SchilkeChief Financial Officer$2,534,794
Dwight MoxieChief Legal Officer$2,244,615

Board service

Revance Therapeutics board · FY2022

How this board is paid

Company policy: Revance Therapeutics pays directors a $50,000 cash retainer and $225,000 in RSUs/Options. As stated in Revance Therapeutics's FY2022 proxy.

The full Revance Therapeutics compensation record

free company brief

This page is one person within Revance Therapeutics's record. The company brief lists every named executive, each linking to their own page.

Peer companies

named in the Revance Therapeutics proxy · each links to its own free brief

Compensation, the day it’s disclosed

The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them.

How this record is built

Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are Revance Therapeutics's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.

Aubrey Rankin's compensation dossier · One-time report. No refunds.